FDA approves BMY’s Opdualag—a_co-formulated_FDC_of Opdivo and anti-LAG-3 relatlimab—in first-line melanoma: https://finance.yahoo.com/news/u-food-drug-administration-approves-222900124.html The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232). In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity. My abbreviated take: https://twitter.com/DewDiligence/status/1395141087413538822